The Role of Hypofractionated Radiotherapy in Prostate Cancer. by Benjamin, LC et al.
GENITOURINARY CANCERS (DP PETRYLAK AND JW KIM, SECTION EDITORS)
The Role of Hypofractionated Radiotherapy in Prostate Cancer
Linus C. Benjamin1 & Alison C. Tree1,2 & David P. Dearnaley1,2
Published online: 25 March 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Purpose of Review It is now accepted that prostate cancer has
a low alpha/beta ratio, establishing a strong basis for
hypofractionation of prostate radiotherapy. This review focus-
es on the rationale for hypofractionation and presents the ev-
idence base for establishing moderate hypofractionation for
localised disease as the new standard of care. The emerging
evidence for extreme hypofractionation in managing localized
and oligometastatic prostate cancer is reviewed.
Recent Findings The 5-year efficacy and toxicity outcomes
from four phase III studies have been published within the last
12 months. These studies randomizing over 6000 patients to
conventional fractionation (1.8–2.0 Gy per fraction) or mod-
erate hypofractionation (3.0–3.4 Gy per fraction). They dem-
onstrate hypofractionation to be non-inferior to conventional
fractionation.
Summary Moderate hypofractionation for localized prostate
cancer is safe and effective. There is a growing body of evi-
dence in support of extreme hypofractionation for localized
prostate cancer. Extreme hypofractionation may have a role in
managing prostate oligometastases, but further studies are
needed.
Keywords Prostate cancer . Radiotherapy .
Hypofractionation . CHHiP . HYPRO
Introduction
Prostate cancer (PCa) is the second most commonly diag-
nosed male malignancy [1] in the Western world, with the
majority of patients having organ-confined disease at presen-
tation [2].
Radical or curative radiotherapy has been traditionally giv-
en with a conventionally fractionated schedule, using daily
dose of 1.8–2.0 Gy over 7–8 weeks, to a total dose of 74–
79.2 Gy.
The dose of 1.8–2.0 Gy per fraction in conventional frac-
tionation (CF) is based on the presumed relative sensitivity of
malignant and normal tissue. The radiobiology and response
of tumours and normal tissue to total dose and dose per frac-
tion has been the subject of intense research for more than
30 years [3, 4]. These studies led to the development of the
linear-quadratic model, which describes the relationship be-
tween cell survival, dose and dose per fraction [5]. In the
linear-quadratic model, the response of tissue to fraction size
is described by the alpha/beta ratio (α/β). The α/β for most
tumours is >8 Gy, while that for late-responding normal tissue
is estimated at 3–4 Gy. For these tumours, CF at 1.8–2.0 Gy
per fraction results in an improvement in the therapeutic ratio.
In parallel advances in physics, engineering, computing
and imaging have been channelled into the development of
image-guided intensity-modulated radiotherapy. The im-
provements in imaging give better target definition, and it is
now possible to accurately deliver highly conformal
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treatment. This has made it possible to both reduce radiation-
related side-effects and escalate dose. Several phase III studies
in prostate cancer have shown that increasing dose, improves
biochemical disease-free survival, with acceptable acute and
long-term toxicities [6–9]. If CF is used, dose-escalated radio-
therapy is now the standard of care.
Dose escalation has been achieved through and increase in
the number of fractions delivered. This has resulted in prolon-
gation of total treatment time, with an increased number of
hospital visits for patients, as well as greater departmental
workload and higher costs. With an improvement in the un-
derstanding of the radiobiology of PCa, hypofractionation has
become an attractive means of dose escalation, without
prolonging treatment duration.
Rationale for Hypofractionation
The theoretical basis for hypofractionation in PCa is the com-
paratively low α/β for PCa. Evidence supporting the hypoth-
esis for a very low α/β for PCa has become available in the
last two decades, including pre-clinical and clinical data. In
1999, a study of 367 patients calculated an α/β of 1.5 Gy
(95% CI 0.8–2.2) [10]. A subsequent study [11] with 1020
patients treated with external beam radiotherapy and brachy-
therapy derived the same value (1.5; 95% CI 1.25–1.75).
These early findings have been supported in a retrospective
analysis of 6000 patients treated with external beam radiother-
apy [12], which calculated an α/β of 1.4 (95% CI 0.9–2.2),
with no significant difference in the calculated ratio between
different risk groups or with androgen deprivation. In con-
junction with other studies [13–15], the α/β of PCa can be
estimated at 1.4–1.9 Gy. This estimate does not take into ac-
count the potential effects of treatment duration or accelerated
repopulation [14].
The low α/β estimates for PCa suggest a greater sensitivity
to increasing fraction size, raising the possibility of dose-
escalation through hypofractionation. The α/β for dose-
limiting organs in prostate radiotherapy is postulated to be
comparatively higher (rectum and bladder; α/β 3–5 Gy).
This forms the theoretical basis for an improvement in the
therapeutic ratio of radiotherapy with larger fraction sizes,
while delivering an isoeffective dose to the prostate.
Moderate Hypofractionation
Moderate hypofractionation (MH) refers to the delivery of
2.4–4.0 Gy per fraction, daily, over 4–6 weeks.
Two systematic reviews [16, 17] of the randomized
evidence for prostate MH had previously concluded that
there was insufficient evidence to demonstrate that MH
produces improved outcome compared to CF. However,
new data from four randomized studies published within
the last 12 months [18••, 19–21, 22•, 23•, 24•] are now
available. Collectively, 6357 patients have been random-
ized to CF (1.8–2.0 Gy per fraction) or MH (3.0–
3.4 Gy per fraction), and 5-year efficacy outcomes and
toxicity profiles have been reported. These results show
that MH is as well tolerated and as clinically effective
as CF, with the obvious economic and practical advan-
tages associated with shorter treatment durations.
Moderate Hypofractionation for Localized Disease
Randomized data comparing MH to CF includes two early
trials, four modern superiority trials, and three modern non-
inferiority trials (Table 1).
Early Studies
The earliest randomized studies in MH were undertaken in
Canada [25] and Australia [26] and gave conflicting results.
Their design was motivated by logistical benefits of shorter
treatment durations, in countries where patients had to travel
considerable distances for radiotherapy. The doses in the arms
these early studies were not isoeffective, as no assumptions
about the α/β of PCa were made in the design of the trials.
The Canadian trial [25] enrolled 936 patients with low- or
intermediate-risk disease, randomizing them to 66 Gy/33 frac-
tions/6.6 weeks or 52.5 Gy/20 fractions/4 weeks. The biolog-
ically effective dose (BED) in the hypofractionated arm was
lower than that in the standard arm. The study reported higher
rates of 5-year biochemical failure (60 vs 53%; p<0.05) and
acute grade 3/4 gastrointestinal (GI) and genitourinary (GU)
toxicity (11 vs 7%) in the hypofractionated arm.
However, after a median follow-up of 5.7 years, there was
no difference in late GI/GU toxicity (≥grade 3 late toxicity
3.2%) between the two study arms.
The Australian trial [26] randomized 217 patients, with
favourable risk PCa, to 64 Gy/32 fractions/6.4 weeks or
55 Gy/20 fractions/4 weeks. Treatment was delivered using
a 2D, four-field box, technique.
After a median follow-up of 90 months, biochemical
disease-free survival was significantly better for the
hypofractionated arm (53 vs 34%; p<0.05), with no signifi-
cant difference in GI/GU toxicity or overall survival.
Multivariate analysis revealed CF to be an independent pre-
dictor for biochemical failure and GU toxicity at 4 years.
While these early studies demonstrated the feasibility of
MH, their toxicity and efficacy outcomes are not applicable
in modern radiotherapy, as the radiotherapy techniques and
doses employed in these studies are no longer in keeping with
the current standard of care.
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Modern Studies
The modern MH trials assume that the α/β for PCa is 1.5 Gy,
and have complementary design, addressing different hypoth-
eses. The superiority studies hypothesize a greater efficacy of
hypofractionation with equivalent toxicity, while the non-
inferiority studies aim to demonstrate equivalent efficacy with
reduced or similar toxicity.
There are three large randomized non-inferiority trials
(CHHiP [18••, 19, 27], RTOG 0415 [23•] and PROFIT
[24•]) evaluating the equivalence of MH and CF. The doses
in the MH arms in these studies range from 57 to 70 Gy in
2.5–3.4 Gy per fraction. Overall, these studies demonstrate
that the safety and efficacy of MH is similar to that of CF.
The largest non-inferiority randomized study of MH is the
CHHiP study [18••, 19, 27]. This study enrolled 3216 patients
from 71 centres in the UK, Ireland, Switzerland and New
Zealand. Patients were randomized to 74 Gy/37 fractions/
7.4 weeks, 60 Gy/20 fractions/4 weeks, or 57 Gy/19 frac-
tions/3.8 weeks, with treatment delivery using IMRT. The
experimental fractionation schedule were designed to be
isoeffective for α/β of 2.5 Gy (60-Gy schedule) and 1.5 Gy
(57-Gy schedule). Twelve, 73, and 15% of patients in this
study had low-, intermediate- or high-risk disease, respective-
ly. Short-course hormonal therapy was mandated for patients
with intermediate- or high-risk disease.
The primary end point in the CHHiP study was time to
biochemical failure, with the critical hazard ratio for non-
inferiority being 1.208.
After a median follow-up of 62.4 months, the 5-year bio-
chemical or clinical failure-free survival was found to be
88.3% in the 74-Gy arm (95% CI 86.0–90.2), 90.6% in the
60-Gy arm (95% CI 88.5–92.3), and 85.9% in the 57-Gy arm
(95% CI 83.4–88.0). The 60-Gy arm was non-inferior to the
74 Gy (HR 0.84, 90% CI 0.68–1.03; pNI=0.0018). The 57-
Gy arm was not non-inferior to the 74-Gy arm (HR 1.20, 90%
CI 0.99–1.46). Overall mortality in each arm was similar; 8.6,
6.8 and 8.1% in the 74, 60 and 57-Gy arm, respectively. There
were no statistically significant differences between the arms
with respect to distant metastasis rate (3.0, 2.7 and 3.9% for
the 74, 60 and 57Gy arms, respectively).
While acute RTOG GI/GU toxicity had become similar in
each arm by 18 weeks, i t peaked ear l ier in the
hypofractionated arm (4–5 weeks) compared to the control
arm (7–8 weeks). Early GI ≥grade 2 toxicity was significantly
higher in the hypofractionated arms; it was 25% in the 74-Gy
arm, 38% in the 60-Gy arm (p<0.0001) and 38% in the 57-Gy
arm (p<0.0001).
5-year clinician and patient-reported side-effects were not
significantly different. RTOG grade ≥2 GI toxicity was report-
ed at 13.7, 11.9 and 11.5% in the 74-, 60- and 57-Gy arms
respectively. Grade ≥2 GU toxicity was reported at 9.1, 11.7
and 6.6% in the 74-, 60- and 57-Gy arms, respectively.
Comparison of the 60- and 57-Gy arms revealed a slightly
higher rate of cumulative LENT-SOM grade ≥2 GI toxicity
(HR 1.39, 95% CI 1.14–1.70; p=0.001) and GU toxicity (HR
1.58, 95% CI 1.13–2.20; p=0.007).
The CHHiP [18••, 19, 27] study provides compelling evi-
dence for hypofractionation, with the authors recommending
60 Gy/20 fractions/4 weeks becoming the new standard of
care for the management of localized PCa.
The PROFIT study (NCT00304759) has recently been pre-
sented [24•]. The critical hazard ratio for non-inferiority in this
study was set at 1.32. PROFIT [24•] recruited 1206 men with
intermediate-risk disease, randomizing them to 60 Gy/20 frac-
tions/4 weeks or 78 Gy/39 fractions/7.8 weeks. All patients in
PROFIT [24•] had intermediate-risk disease, with none re-
ceiving hormonal therapy.
After a median follow-up of 6 years, no significant differ-
ence in 5-year biochemical failure (HR 0.96, 90% CI 0.80–
1.15), acute ≥grade 3 GI/GU toxicity, or overall survival have
been reported. Interestingly late toxicity was lower in the MH
arm (3.5 vs 5.4%, difference=−1.9%, 95% CI −4.3 to 0.43).
The authors of PROFIT [24•] conclude that, for patients
with intermediate-risk disease, MH is non-inferior to CF, for
both efficacy and acute/late toxicity.
The RTOG 0415 [23•] study randomized 1092 patients,
with low-risk disease, to 73.8 Gy/41 fractions/8.2 weeks or
70 Gy/28 fractions/5.6 weeks. The critical hazard ratios for
non-inferiority were set at 1.52 for 5-year disease-free survival
(primary end point), 1.67 for cumulative biochemical recur-
rence and 1.54 for overall survival.
After a median follow-up of 5.8 years, the MH arm was
reported to be non-inferior to the CF arm with respect to 5-
year disease-free survival (HR 0.85, 95% CI 0.64–1.14;
p<0.001), biochemical recurrence (HR 0.77, 95% CI 0.51–
1.17; p<0.001) and overall survival (HR 0.95, 95% CI 0.64–
1.41; p=0.008).
The acute side effects did not differ significantly in the two
arms of the study. The MH arm had a significantly higher rate
of grade 2–3 late GI toxicity (22.4 vs 14%; RR 1.55–1.59) and
grade 2–3 late GU toxicity (29.7 vs 22.8%; RR 1.31–1.59).
The authors concluded that the efficacy of MH is not infe-
rior to CF, though the late grade 2–3 GI/GU toxicity is higher.
CHHiP [18••, 19, 27], RTOG 0415 [23•] and PROFIT
[24•] include patients in different risk groups and differ in
the use of hormonal therapy, but all studies give very similar
hazard ratios (<1.0) for their primary end points, demonstrat-
ing that the efficacy of MH is not inferior to CF. They differ in
their late toxicity outcomes.
In contrast to RTOG 0415 [23•],CHHiP [18••, 19, 27] has
reported no difference in late toxicity, while PROFIT [24•]
reports a lower rate of late toxicity in the hypofractionated
arm. These differences may partly be accounted for by the
BED in the hypofractionated and control arms of each study.
Assuming an α/β of 3.0 Gy for bladder/rectum, the BED in
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the hypofractionated arm is higher than the control arm in
RTOG 0415 (128 Gy vs 118 Gy), similar to the control arm
in CHHiP [18••, 19, 27] (120 Gy vs 123 Gy), and lower than
the control arm in PROFIT [24•] (120 Gy vs 130 Gy).
Comparing PROFIT [24•] and CHHiP [18••, 19, 27], the
use of hormonal therapy in some patients in CHHiP appears to
improve biochemical control by 10%, although the impact of
hypofractionation is similar with or without hormonal therapy.
Finally, the α/β estimated by CHHiP [18••, 19, 27]
(1.8 Gy) and PROFIT [24•] (1.3 Gy) are both in keeping with
the low range of 1.4–1.9 Gy estimated from meta-analyses
and large series [12–15], further re-enforcing the theoretical
basis for MH.
In the four modern MH superiority randomized trials [20,
21, 22•, 28–31], the dose in the MH arms ranges from 62 to
72 Gy in 2.4–3.4 Gy per fraction. Collectively, these studies
have not demonstrated any differences in efficacy after 5 years.
No differences in metastasis-free, cancer-specific survival or
overall survival have been demonstrated.
Hoffman [28, 29] and Pollack [31] compared CF with MH
and found no significant difference in 5-year biochemical
recurrence-free survival.
Arcangeli [30] recruited 168 patients with high-risk PCa,
randomizing them to 80 Gy/40 fractions/8 weeks or 62 Gy/20
fractions/4 weeks, in conjunction with 9 months of hormonal
therapy.
After a median follow-up of 70 months, a non-significant
improvement in actuarial 5-year biochemical recurrence-free
survival was demonstrated in the MH arm (85 vs 79%;
p=0.065). No significant difference in local or distant recur-
rence was demonstrated. However, subgroup analysis of pa-
tients with a PSA ≤20 ng/ml revealed a significant improve-
ment in 5-year local and distant disease control, in addition to
biochemical control.
The HYPRO study [20, 21, 22•] is the largest of the MH
superiority studies. HYPRO randomized 804 patients, with
intermediate- or high-risk disease to 64.6 Gy/19 fractions/3
fractions per week/6.5 weeks or 78Gy/39 fractions/5 fractions
per week/7.8 weeks. The majority of patients in this study
were high-risk (>70%), with 66% receiving concomitant hor-
monal therapy. The primary end point was 5-year relapse-free
survival. An additional, non-inferiority, end point was the in-
cidence of ≥grade 2 GI/GU toxicity, with a critical hazard ratio
designated as 1.11/1.13, respectively.
After a median follow-up of 60 months, the 5-year relapse-
free survival was not statistically different in the MH and CF
arms (77.1 vs 80.5%; p=0.36).
No differences in acute ≥grade 2 GU toxicity were reported
between the MH (60.5%, 95% CI 55.8–65.3) and CF arms
(57.8%, 95% CI 52.9–62.7%). However, the cumulative inci-
dence for acute ≥grade 2 GI toxicity was significantly higher
(OR 1.6; p=0.0015) in the MH arm (42%, 95% CI 37.2–
46.9%) compared to control (31.2%, 95% CI 26.6–35.8%).
Furthermore, the cumulative incidence of late ≥grade 3 GU
toxicity was significantly higher in the MH arm (19 vs 12%;
p = 0.021). No statistically significant difference in
cumulative≥grade 3 late gastrointestinal toxicity was found
the two study arms (2.6 vs 3.3%).
In contrast to CHHiP [18••, 19, 27] and PROFIT [24•],
HYPRO [20, 21, 22•] concludes that hypofractionation is
not non-inferior to CF, with respect to ≥grade 3 late GU
toxicity.
For similar reasons to the higher toxicity seen in RTOG
0415 [23•], the higher late toxicity in HYPRO [20, 21, 22•]
may relate to a higher BED delivered to organs at risk in the
hypofractionated arm of HYPRO.
Additionally, compared to CHHiP [18••, 19, 27], HYPRO
[20, 21, 22•] included a greater proportion of the seminal vesicles
in the high-dose volume, which may account for the higher late
toxicity. In HYPRO, patients with >10% risk of seminal vesicle
involvement had their seminal vesicle included in the high-dose
volume. Patients with a 10–25% probability of seminal vesicle
involvement received a total dose of 70–72.15 Gy/1.85–2.0 Gy
per fraction in the control arm or 54.4–57.76Gy/3.04–3.4Gy per
fraction in the hypofractionated arm. For patients with a >25%
risk of seminal vesicle involvement, the seminal vesicles were
treated to the full dose of 78 Gy or 64.6 Gy in each respective
arm. By contrast, in CHHiP [18••, 19, 27], patients with >15%
risk of seminal vesicle involvement received 96% of the pre-
scribed dose to the base of the seminal vesicles, and 80% of
the prescribed dose to the seminal vesicles, within each arm.
The outcome of HYPRO [20, 21, 22•] is in keeping with
other superiority hypofractionation trials, which did not dem-
onstrate an improvement in efficacy outcomes with
hypofractionation. Assuming α/β ratio of 1.5 Gy for PCa,
the 2 Gy equivalent dose in the hypofractionated arm of
HYPRO is 90.4 Gy. This dose escalation, over the control
arm of 78 Gy/39 fractions, may have been expected to have
resulted in a significant improvement in biochemical control.
Its failure to do somay relate to the longer duration over which
treatment was delivered (6.5 weeks), compared to other
hypofractionation schedules.
Extreme Hypofractionation
Extreme hypofractionation (EH) using stereotactic body radio-
therapy (SBRT) refers to the delivery of 6–10 Gy per fraction
either daily, on alternate days or weekly, to a total dose of 35–
50 Gy (Fig. 1). While the linear-quadratic model predicts an
improvement in therapeutic ratio with MH, its applicability to
EH has been questioned [32], because it does not account for
vascular and stromal tissue injury occurring at EH. However, this
criticism relates to doses above 10 Gy per fraction, which are not
used in EH of PCa radiotherapy [33]. At doses below 10 Gy per
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fraction, the linear-quadratic model seems to predict tumour con-
trol well, without the need for additional factors [34].
Extreme Hypofractionation for Localized Disease
Two systematic reviews [16, 17] have recommended that EH be
only pursued in the setting of a clinical trial, owing to the absence
of long-term data. In the last decade, phase I–II data using either
IMRT [35–38] or non-coplanar techniques [39–45] have dem-
onstrated toxicity and efficacy outcomes of EH being compara-
ble to CF. Patient-reported quality-of-life outcomes are similar
between IMRT, SBRT and LDR brachytherapy at 2 years [46].
SBRTcompares favourably with IMRTand LDR brachytherapy
in terms physician-reported toxicity outcomes [47].
Outcomes with prostate SBRT have been encouraging
for doses between 33.5 and 40 Gy/6.7–8.0 Gy per fraction.
Based on a study by Kim [38], doses > 9Gy per fraction to
a total of >45Gy to the whole prostate are not recommend-
ed, owing to higher risk of toxicity. In this dose-escalation
SBRT study, patients with low-intermediate-risk disease,
received 45 Gy/5 fractions/9 Gy per fraction, 47.5 Gy/5
fractions/9.5 Gy per fraction, or 50 Gy/5 fractions/10 Gy
per fraction. After a median follow-up of 24 months, 6.6%
of patients treated with 50 Gy/5 fractions had ≥grade 3 late
rectal toxicity.
Studies treating patients to 33.5–36.25 Gy/5 fractions/6.7–
7.25 Gy per fraction have reported good early outcomes with
acceptable toxicities.
Madsen [35] treated 40 patients to a dose of 33.5Gy/5 daily
fractions/6.7 Gy per fraction. After a median follow-up of
41 months, biochemical disease-free survival was 90%, with
no incidence of≥grade 3 GI/GU toxicity. Grade 2 GU/GI
toxicity was reported at 20 and 8%, respectively.
Loblaw [36] treated 84 patients with low-risk disease, with
35 Gy/5 weekly fractions/7 Gy per fraction. After a median
follow-up of 55 months, biochemical relapse-free survival was
reported at 98%. No acute GU toxicity ≥grade 3 was reported.
Late grade 2 GU/GI toxicity was 7 and 5%, respectively.
Chen [41] treated 100 low-high-risk patients with
36.25 Gy/5 alternate day fractions/7.25 Gy per fraction.
After a median follow-up of 27 months, the biochemical
disease-free survival was 99%, with no acute ≥grade 3 GI/
GU toxicity. The late ≥grade 3 GU toxicity rate was 1%.
Grade 2 acute and chronic GU toxicity was 35 and 31%,
respectively (CTCAE); this is higher than that reported in
other studies [40, 44], primarily as it relates to the use of α-
antagonists in the study. The higher reported toxicity, did not
have a significant impact on patients’ long-term quality of
life [49]. Acute and late GI toxicity was 5 and 1%,
respectively.
The above studies measured acute toxicity only once in the
first 3 months after SBRT. Studies that have evaluated acute
toxicity more than once in the first 3 months after SBRT [42,
50] have reported higher toxicity rates.
Bolzicco [42] treated 100 patients with low-high-risk dis-
ease, with 35 Gy/5 daily fractions/7 Gy per fraction. No acute
grade 3 toxicity was reported. Acute GI/GU toxicity was 18
and 12%, respectively. Late GI/GU toxicity was 1 and 3%,
respectively. The biochemical relapse-free survival was 95%
after a median follow-up of 36 months.
Tree [50] has reported on a series of 51 patients treated with
36.25 Gy/5 alternate day fractions/7.25 Gy per fraction. Acute
grade 2 GU/GI toxicity was 22 and 14%, respectively, with
4% of patients having acute grade 3 urinary toxicity.
Long-term outcomes for prostate SBRT have been reported
by Meier [45] and King [48].
A multi-institutional study [45] recruited 309 patients,
with low-intermediate-risk disease, treating the prostate
to 40 Gy/5 fractions/8 Gy per fraction and the seminal
vesicles to 36.25 Gy/5 fractions/7.25 Gy per fraction.
After a median follow-up of 61 months, 1.6% of patients
reported grade 3 toxicity, all of which were GU toxic-
ities. No grade 4–5 toxicity was reported. The 5-year
overall survival and biochemical disease-free survival
rates were 95.6 and 97.1% respectively.
King performed a pooled analysis of 1100 patients, treated
with SBRT [48]. Eleven percent of patients had high-risk dis-
ease. At a median follow-up of 36 months, the 5-year bio-
chemical disease-free survival for low-, intermediate- and
high-risk disease was 95, 84, and 81%, respectively.
While the phase I–II data on prostate SBRT is encouraging,
the phase III data is eagerly awaited. There are two phase III
studies comparing EH with CF.
The Swedish HYPO trial (ISRCTN45905321) has ran-
domized 592 patients, with intermediate-risk disease to CF
or 42.7 Gy/7 alternate day fractions/6.1 Gy per fraction.
Fig. 1 Treatment plan and dose statistics for prostate SBRTwith a non-
coplanar technique. (Acknowledgement: Dr Nicholas van As, Kirsty
Morrison, Royal Marsden Hospital, UK)
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The PACE B study (NCT01584258) is ongoing, and ran-
domizes patients to CF or 36.25 Gy/5 fractions/7.25 Gy per
fraction/5 days. In view of the recently published CHHiP
study [18••], a hypofractionated protocol amendment has been
developed for PACE B, allowing 62 Gy/20 fractions/3.1 Gy
per fraction/4 weeks.
The PATRIOT study is evaluating alternate day (treatment
duration 11 days) versus weekly (treatment duration 29 days)
stereotactic prostate radiotherapy. This study, delivers 40 Gy/5
fractions/8 Gy per fraction to the prostate and evaluates bowel
quality-of-life parameters. Early results suggest superior qual-
ity of life with respect to bowel and urinary function, in the
first 3 months following treatment, in the 29-day arm of the
study [51].
Extreme Hypofractionation in Oligometastatic Disease
Oligometastatic PCa, referring to ≤3 isolated sites of metasta-
tic disease, is increasingly being diagnosed, partly because of
the development of sophisticated imaging techniques.
Historically, the treatment of oligometastatic disease has been
identical to that of polymetastatic disease; however,
oligometastatic disease may represent a biologically distinct
clinical state [52]. Aggressive treatment of oligometastases
may help eliminate castrate-resistant clones, delay the devel-
opment of castrate-resistant disease and thereby potentially
improve survival [53].
The data on EH for oligometastatic disease is limited. The two
largest studies of SBRT in oligometastatic disease each had 50
patients with predominantly nodal or osseous disease [54, 55].
Decaestecker [54] treated metastases to 50 Gy/10 fractions
with 1 month of hormonal therapy or 30 Gy/3 fractions with-
out hormonal therapy. The median progression-free survival
was 19 months, and a 2-year progression-free survival of
35%. Grade 2 toxicity was reported in 6% of patients.
Schick [55] reported 3-year progression-free survival of
59%. In comparison to the Decaestecker study, the Schick
study treated a greater proportion of patients (98 vs 70%) with
longer duration of hormonal therapy (1 year vs 1 month).
Additionally, in those patients treated for oligometastic nodal
disease, more patients received prophylactic irradiation in the
Schick study (61 vs 0%).
Jereczek-Fossa [56] treated 19 patients with predominantly
pelvic nodal oligometastatic disease to a dose of 33–36 Gy/3
fractions; all patients were receiving between 12 and
17 months of hormonal therapy. The 30-month progression-
free survival was 63.5%.
Casamassima [57] treated 25 patients with nodal
oligometastatic disease, to 30Gy/3 fractions, without hormon-
al therapy. The median progression-free survival was
24 months, with no ≥grade 2 toxicity.
Muacevic [58] reported on 40 patients with mainly spinal
oligometastatic osseous disease. An actuarial 2-year local
tumour control rate, as measured by MRI and PET-CT was
reported at 95.5%.
A systematic review of retrospective studies [59] reported
on 299 patients with oligometastatic disease treated with ra-
diotherapy, 55% of whom were treated with extreme
hypofractionation. Of the data available for acute toxicity,
grade 1–2 toxicity was reported in 15% of patients, with grade
3 toxicity in 0.7%.
Pooled analysis of 119 patients, with ≤3 metastases, treated
with SBRT has been reported by Ost [60, 61]. The local con-
trol was found to be superior when SBRT delivered a BED
≥100 Gy. No ≥grade 3 toxicities were reported, with 3% of
patients reporting grade 2 toxicity. The 3-year distant
progression-free survival was reported at 31%.
Pooled analysis [60] of a subset of 72 patients with
oligorecurrent nodal disease, treated with SBRT at a dose of
5Gy per fraction to a BED of at least 80Gy, has reported a
median distant progression-free survival of 21 months, with a
progression-free survival of 34%/13% at 3/5 years, respective-
ly. Late grade 1 and 2 toxicity was reported in 17 and 4% of
patients, respectively.
From these studies, SBRT appears to achieve local control
of oligometastatic disease; however, randomized studies are
needed to establish its impact on progression-free survival and
overall survival.
Several prospective studies are currently underway evalu-
ating SBRT in oligometastatic disease (the phase II CORE
study NCT02759783, the SABR-COMET study
NCT01446744, the STOMP study NCT01558427, the
ORIOLE study NCT02680587).
Conclusions
Moderate hypofractionation for localized PCa is safe and ef-
fective. Based on several large randomized studies,
hypofractionation at around 3 Gy per fraction can be consid-
ered a standard of care for localized PCa.
There is a growing body of evidence in support of extreme
hypofractionation for localized PCa. Comparative data and
the data from several randomized studies are awaited.
Prostate oligometastases represent another scenario where ex-
treme hypofractionation may have a role but the results of
ongoing studies are needed before this is considered the stan-
dard of care.
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